Xerava (Eravacycline) for Complicated Intra-Abdominal Infections: Fluorocycline Antibiotic Explained (FDA Approved 2018)
Quick answer: Xerava (eravacycline) is a fully synthetic, intravenous antibiotic in the tetracycline class. The U.S. Food and Drug Administration approved it on August 27, 2018, for adults aged 18 and older with complicated intra-abdominal infections (cIAI), such as appendicitis with perforation, peritonitis, diverticular abscess, and intra-abdominal abscess. Two phase 3 trials, IGNITE1 and IGNITE4, found it noninferior to the carbapenems ertapenem and meropenem for clinical response. Xerava is not approved for urinary tract infections, because the IGNITE2 and IGNITE3 urinary trials did not meet noninferiority. Like other tetracyclines, it carries class warnings, and it is given only in healthcare settings. Treatment decisions belong to your surgical and infectious disease team.
Reading time: about 10 to 12 minutes. This article is educational and does not replace medical advice. Abdominal infections can become life-threatening quickly. If you have severe abdominal pain, fever, or vomiting, seek emergency care now.
Why Abdominal Infections Are Dangerous
What Counts as Complicated
Complicated intra-abdominal infections are infections that extend beyond a hollow organ into the abdominal cavity. Examples include appendicitis with perforation, gallbladder infection with rupture, diverticulitis with abscess, and peritonitis from bowel perforation. These infections often require both source control, such as drainage or surgery, and antibiotics.
Mixed Bacteria Make Treatment Harder
Abdominal infections are usually polymicrobial, meaning several types of bacteria are involved at once. Gram-negative organisms such as E. coli and Klebsiella, gram-positive organisms such as enterococci and streptococci, and anaerobes such as Bacteroides are common. Antibiotics for these infections need to cover that mix.
Why Resistance Matters
Resistant organisms, including some that produce ESBLs or carbapenemases, can make empiric therapy harder to choose. Clinicians often turn to carbapenems for severe infections, which is why alternatives that work in some of these settings are valuable.
Key Takeaways
- Xerava (eravacycline) received FDA approval on August 27, 2018, for adults 18 and older with complicated intra-abdominal infections.
- It is a fully synthetic fluorocycline in the tetracycline class, given only by intravenous infusion.
- In IGNITE1 and IGNITE4, eravacycline was noninferior to ertapenem and meropenem for clinical response in cIAI.
- It is not approved for complicated urinary tract infections, because the IGNITE2 and IGNITE3 urinary trials did not show noninferiority.
- Trial and approval coverage reported that no renal dose adjustment was needed, but current labeling should be confirmed.
- Like other tetracyclines, Xerava carries class warnings. Source control with drainage or surgery remains essential for most abdominal infections.
What Is Xerava
Brand and Generic Names
Xerava is the brand name for eravacycline, developed by Tetraphase Pharmaceuticals. The product was later associated with Innoviva Specialty Therapeutics in the United States. It is supplied as an injection for intravenous use.
Drug Class
Eravacycline is a fluorocycline, a fully synthetic member of the tetracycline class. It is structurally related to tigecycline, another IV tetracycline-class antibiotic used for serious infections.
Why a New Tetracycline Was Developed
Many older tetracyclines have lost effectiveness against resistant bacteria through efflux pumps and ribosomal protection. Eravacycline was designed to overcome several of these resistance mechanisms while keeping the tetracycline core that targets bacterial protein synthesis.
FDA Approval: August 27, 2018
The Decision
The FDA approved Xerava on August 27, 2018. Tetraphase announced the approval the same week. The labeled population is adults aged 18 and older with complicated intra-abdominal infections.
Basis for Approval
The approval rested on two phase 3 trials of cIAI, IGNITE1 and IGNITE4, which compared eravacycline with carbapenem comparators. Both trials showed noninferiority for the primary clinical response endpoint.
What the Approval Does Not Cover
The label does not include complicated urinary tract infections. Eravacycline was studied for urinary infections, but the trials did not establish noninferiority, so no urinary indication was approved.
Where Xerava Fits in the Tetracycline Family
A Familiar Class
Tetracyclines such as doxycycline and minocycline are widely used for many infections and are inexpensive. They share a core structure that binds the bacterial ribosome. Many people know them from acne or respiratory infections.
A Different Role
Xerava is not a substitute for everyday tetracyclines. It is an IV-only drug with its own labeled use, designed for serious abdominal infections in hospitalized patients. Doxycycline and minocycline have different approved uses and formulations.
Related Reading
If you want to learn more about the oral tetracycline most people encounter, see what doxycycline hyclate 100 mg is used for. That article covers oral use, which is different from the IV use described here.
How Eravacycline Works
Protein Synthesis Inhibition
Eravacycline binds to the bacterial 30S ribosomal subunit and blocks the addition of amino acids to growing proteins. Without functional proteins, bacteria cannot grow and replicate. Tetracycline-class drugs are generally considered bacteriostatic, so the immune system and source control play key roles in clearing infection.
Overcoming Resistance
Eravacycline's structure helps it remain active against some organisms that carry tetracycline efflux or ribosomal protection genes. Laboratory activity does not guarantee clinical success, so susceptibility testing and clinical judgment still matter.
Why Source Control Matters
An abscess or perforation can keep bacteria growing despite good drug levels. Surgeons or interventional radiologists often drain the infection, and antibiotics support that work.
Which Bacteria It Targets
Labeled Organisms
The label for cIAI lists susceptible organisms, including Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, and Bacteroides species. Confirm the complete list in the current prescribing information.
Mixed Infection Coverage
Because cIAI is usually polymicrobial, the drug's spectrum covers gram-negative, gram-positive, and anaerobic organisms that commonly appear together in these infections.
Limits
Some resistant organisms, including certain carbapenem-resistant strains, may not respond. Culture results guide whether eravacycline remains the right choice.
Approved Use and Labeling Limits
Who Is Eligible
The approved population is adults aged 18 and older with cIAI. Typical diagnoses include appendicitis, cholecystitis, diverticulitis with complications, gastric or duodenal perforation, intra-abdominal abscess, and peritonitis.
Stewardship Statement
The label directs use only for infections proven or strongly suspected to be caused by susceptible bacteria. This language supports careful use and helps preserve the drug's effectiveness.
Not Approved For
Xerava is not approved for complicated urinary tract infections, uncomplicated infections, or children under the labeled age range. Decisions outside labeled uses rest with the treating clinicians.
The IGNITE1 Trial
Design
IGNITE1 was a randomized, double-blind, multicenter phase 3 trial comparing intravenous eravacycline with intravenous ertapenem in hospitalized adults with cIAI. The trial enrolled 541 patients.
Dosing in the Trial
Eravacycline was given at 1 mg/kg every 12 hours. Ertapenem was given at 1 gram every 24 hours. Both arms received at least four cycles of treatment, consistent with how cIAI is managed.
Primary Outcome
The primary outcome was clinical response at a test-of-cure visit. Clinical cure rates were similar, at about 86.8 percent for eravacycline and 87.6 percent for ertapenem in the reported analysis.
The IGNITE4 Trial
Design
IGNITE4 was a randomized, multicenter phase 3 trial comparing eravacycline with meropenem in adults with cIAI. The trial enrolled 499 patients.
Dosing in the Trial
Eravacycline was given at 1 mg/kg every 12 hours. Meropenem was given at 1 gram every 8 hours, reflecting the standard carbapenem regimen for serious infections.
Primary Outcome
The primary outcome was clinical response in the microbiologic population. The trial showed that eravacycline was noninferior to meropenem.
Trial Results Explained
Noninferiority Explained
Both IGNITE trials were noninferiority studies. They showed eravacycline performed about as well as the carbapenem comparators within a set margin. They do not prove it is more effective.
Safety in the Trials
Coverage of the trials described eravacycline as well tolerated, with safety profiles that were generally comparable to the comparators. Specific adverse-event rates should be checked in the prescribing information.
Reading the Numbers
Trial populations are selected, and real-world patients may be older, sicker, or have different organisms. Surgical source control and supportive care also shape outcomes, which trials only partly capture.
Why It Is Not Approved for Urinary Infections
The IGNITE2 and IGNITE3 Trials
Two additional phase 3 trials, IGNITE2 and IGNITE3, studied eravacycline in complicated urinary tract infections. They compared it with levofloxacin and ertapenem, respectively. Eravacycline did not demonstrate noninferiority in these trials.
What This Means
Because the urinary trials did not meet their criteria, the FDA did not approve eravacycline for cUTI. Patients with urinary infections need evaluation for other options.
A Lesson in Labeling
The contrast between the cIAI approval and the cUTI result shows why labels matter. A drug can be effective in one infection type and not another, even within the same tetracycline class.
Dosing and Administration
IV Infusion
Xerava is given by intravenous infusion, typically in a hospital setting. Nurses and pharmacists prepare the drug and monitor the infusion.
Labeled Regimen
The trial regimen was 1 mg/kg every 12 hours. Current dosing, infusion time, and duration should be confirmed in the prescribing information on DailyMed.
Duration
Treatment length depends on the infection, source control, and response. The care team sets the plan and reviews it as the patient improves.
Missed Doses
Hospital staff manage missed or delayed doses. Patients should not try to make up doses on their own.
Kidney Function and Dosing
What Coverage Reported
Coverage at approval reported that eravacycline did not require dose adjustment for patients with renal impairment. Kidney function still matters for overall care, so your team will monitor it.
Why Monitoring Continues
Patients with cIAI may be critically ill, dehydrated, or receiving other nephrotoxic medicines. Those factors can change kidney function quickly.
Verify the Label
Renal guidance can change with labeling updates. Confirm current instructions with the prescribing information.
Common Side Effects
Gastrointestinal Effects
Nausea, vomiting, and diarrhea are among the more frequently reported effects with tetracycline-class antibiotics. Most are mild. Persistent or bloody diarrhea needs prompt evaluation.
Infusion-Site Reactions
Pain, redness, or swelling at the IV site can occur. Report these to your nurse so the line can be checked.
Headache and Lab Changes
Headache and changes in laboratory tests, such as liver enzymes or blood clotting values, may occur. Your team may monitor labs during treatment.
Serious Risks and Warnings
Hypersensitivity Reactions
Serious allergic reactions can occur. Hives, facial swelling, trouble breathing, or fainting require emergency care. Tell your team about any previous reactions to tetracyclines or other antibiotics.
C. difficile Infection
C. difficile can cause severe diarrhea and colitis. Any new or worsening diarrhea during or after treatment should be reported promptly, because it needs its own treatment.
Mortality Concern in Other Settings
Tigecycline, a related IV tetracycline-class drug, carries a boxed warning about all-cause mortality in some populations. Clinicians should read the current Xerava label for its own warnings and apply them to each patient.
Tetracycline Class Warnings
Tooth and Bone Effects
Tetracyclines can cause tooth discoloration and affect bone growth when used during tooth development or in young children. Use in children is restricted for this reason. Pregnant patients need a careful risk-benefit discussion.
Photosensitivity
Tetracyclines can increase sensitivity to sunlight. Use sun protection during treatment and report unusual sunburn.
Intracranial Pressure
Increased pressure around the brain has been reported with tetracyclines. Severe headache, vision changes, or ringing in the ears should be reported promptly.
Who Should Not Receive Xerava
Known Allergy
People with a known allergy to eravacycline or other tetracycline-class drugs should not receive Xerava without specialist review.
Children and Pregnancy
Use in children and pregnancy requires specialist judgment because of the tetracycline class effects on teeth and bones.
Urinary Infections
Xerava is not approved for complicated urinary tract infections. Those infections need different antibiotic evaluation.
Drug Interactions
Medication Review
Give your care team a full list of medications, including prescriptions, over-the-counter products, and supplements. Pharmacists check for interactions before starting any new antibiotic.
Oral Products and Minerals
Tetracyclines can bind minerals such as calcium, iron, magnesium, and zinc. This matters mainly for oral products, but your team will check overall medication timing.
Anticoagulants
Antibiotics can affect how blood thinners work, so clotting tests may be checked during treatment.
How Xerava Compares With Other Options
Ertapenem and Meropenem
These carbapenems were the comparators in the IGNITE trials and remain standard for many serious abdominal infections. Xerava offers an alternative, but choice depends on culture results, severity, and local resistance.
Piperacillin/Tazobactam
Piperacillin/tazobactam is another option for mixed intra-abdominal infections. Its suitability depends on the organisms and the clinical situation.
Tigecycline
Tigecycline is an older IV tetracycline-class antibiotic. It has a boxed mortality warning and a different labeled use, so the two are not interchangeable.
Antibiotics Alongside Surgery
Source Control
Drainage or surgical removal of the source is central to treating most complicated abdominal infections. Antibiotics support source control but do not replace it.
Timing
Antibiotics are usually started promptly, often before cultures return, then adjusted based on results. The surgical team and infectious disease team coordinate the plan.
Recovery
Recovery depends on the infection, the patient's health, and how quickly the source was controlled. Follow your team's instructions about activity, diet, and follow-up.
Antibiotic Stewardship
Use Only When Indicated
Antibiotics should be used when infections are proven or strongly suspected to be bacterial. The label emphasizes this to protect the drug's future usefulness.
Culture First
Cultures from surgery or drainage guide whether the regimen should continue, narrow, or change.
Protecting Carbapenems
Using alternatives where appropriate can help preserve carbapenems for the most serious resistant infections.
Availability and Cost
Availability
Xerava is given in hospital settings. Availability depends on the facility, so your care team can confirm stock.
Cost
Xerava is a branded IV antibiotic. Costs are often bundled into the hospital stay. Ask your insurer or hospital financial counselor for current figures.
Coverage
Coverage for FDA-approved indications is generally more straightforward. Prior authorization may be required.
Pregnancy, Breastfeeding, and Children
Pregnancy
Pregnant patients with intra-abdominal infections need urgent evaluation. Decisions about eravacycline should involve obstetric and infectious disease teams, weighing benefits against the limited data available.
Breastfeeding
Discuss breastfeeding with your care team before treatment.
Children
The label is limited to adults 18 and older. Use in children is outside the labeled indication and requires specialist judgment.
Questions to Ask Your Care Team
- Has the source of infection been drained or removed, and is more source control planned?
- Did cultures identify organisms susceptible to eravacycline?
- Why was this drug chosen over a carbapenem or another option?
- How will my kidney function and blood tests be monitored?
- What signs of diarrhea, allergy, or neurologic change should the nurses report right away?
Frequently Asked Questions
Q: What is Xerava used for?
A: Xerava is approved for adults with complicated intra-abdominal infections, such as appendicitis with perforation, peritonitis, and intra-abdominal abscess.
Q: When was it approved?
A: The FDA approved it on August 27, 2018.
Q: Is Xerava a pill?
A: No. It is given only by IV infusion.
Q: Does Xerava treat urinary infections?
A: No. It is not approved for complicated urinary tract infections, because those trials did not meet noninferiority.
Q: Is it the same as doxycycline?
A: They share a tetracycline core and class warnings, but they are different drugs with different approved uses and formulations.
Q: Does it need kidney dose changes?
A: Coverage at approval reported no renal adjustment was needed, but confirm current labeling with your team.
Q: What should I do about diarrhea during treatment?
A: Tell your care team promptly. Persistent or bloody diarrhea needs evaluation, including testing for C. difficile.
Medical Disclaimer
This article is for general education only and does not provide medical advice, diagnosis, or treatment. Complicated intra-abdominal infections are serious and require emergency or hospital-based care. Do not start, stop, or change any antibiotic without guidance from your care team. For dosing, warnings, and interactions, consult the current U.S. prescribing information on DailyMed. If you have severe abdominal pain, fever with chills, vomiting, or confusion, seek emergency care immediately.
Sources and Further Reading
- U.S. FDA approval of Xerava (eravacycline) for complicated intra-abdominal infections, August 27, 2018
- Tetraphase Pharmaceuticals announcement of FDA approval, August 2018
- Drugs.com Xerava FDA approval history
- IGNITE1 and IGNITE4 phase 3 trial summaries and published reports (Solomkin et al., Clinical Infectious Diseases, 2018)
- IGNITE2 and IGNITE3 urinary trial summaries reporting noninferiority was not demonstrated
- Xerava U.S. Prescribing Information, including warnings and renal dosing guidance
This article reflects information available as of October 2026. Confirm current prescribing details with your healthcare provider and the latest FDA labeling.
